Schwab Charles Investment Management Inc. bought a new position in shares of Savara Inc (NASDAQ:SVRA) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 53,658 shares of the company’s stock, valued at approximately $608,000.
Several other hedge funds have also recently modified their holdings of the stock. Jennison Associates LLC grew its stake in shares of Savara by 1.4% during the second quarter. Jennison Associates LLC now owns 794,234 shares of the company’s stock worth $8,991,000 after purchasing an additional 10,612 shares in the last quarter. Northern Trust Corp grew its stake in shares of Savara by 22.6% during the first quarter. Northern Trust Corp now owns 58,530 shares of the company’s stock worth $539,000 after purchasing an additional 10,779 shares in the last quarter. UBS Group AG grew its stake in shares of Savara by 1,012.8% during the first quarter. UBS Group AG now owns 14,556 shares of the company’s stock worth $133,000 after purchasing an additional 13,248 shares in the last quarter. GSA Capital Partners LLP acquired a new position in shares of Savara during the first quarter worth $134,000. Finally, Citadel Advisors LLC acquired a new position in shares of Savara during the first quarter worth $149,000. Hedge funds and other institutional investors own 41.84% of the company’s stock.
NASDAQ SVRA opened at $10.01 on Friday. The company has a debt-to-equity ratio of 0.16, a current ratio of 10.30 and a quick ratio of 10.30. Savara Inc has a 1 year low of $7.85 and a 1 year high of $17.19. The firm has a market capitalization of $391.65 million, a price-to-earnings ratio of -5.69 and a beta of -0.33.
SVRA has been the subject of a number of analyst reports. HC Wainwright reiterated a “buy” rating and set a $22.00 target price on shares of Savara in a research note on Friday, August 10th. Roth Capital assumed coverage on shares of Savara in a research note on Monday, August 13th. They issued a “neutral” rating and a $12.00 price objective for the company. Zacks Investment Research downgraded shares of Savara from a “hold” rating to a “sell” rating in a research note on Thursday, September 13th. Finally, Canaccord Genuity set a $25.00 price objective on shares of Savara and gave the company a “buy” rating in a research note on Tuesday, August 14th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $26.80.
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Read More: What is the Rule of 72?
Want to see what other hedge funds are holding SVRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Savara Inc (NASDAQ:SVRA).
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.